Abdel-Mohsen, MohamedRichman, DouglasSiliciano, Robert FNussenzweig, Michel CHowell, Bonnie JMartinez-Picado, JavierChomont, NicolasBar, Katharine JYu, Xu GLichterfeld, MathiasAlcamÃ, JoséHazuda, DariaBushman, FredericSiliciano, Janet DBetts, Michael RSpivak, Adam MPlanelles, VicenteHahn, Beatrice HSmith, Davey MHo, Ya-ChiGaebler, ChristianPaiardini, MirkoLi, QingshengEstes, Jacob DHope, Thomas JKostman, JayMounzer, KaramCaskey, MarinaFox, LawrenceFrank, IanRiley, James LTebas, PabloMontaner, Luis JBuzon, Maria J2021-03-032021-03-032020Nat Med . 2020 Sep;26(9):1339-1350.http://hdl.handle.net/20.500.12105/12088Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.engSMURhttp://creativecommons.org/licenses/by-nc-nd/4.0/HIV latencyHIV reservoirsViral measurementsHIV CureHIV persistenceReplication-competent HIVAnti-Retroviral AgentsCD4-Positive T-LymphocytesClinical Trials as TopicDisease ReservoirsHIV InfectionsHIV-1HumansMass ScreeningViral LoadVirus LatencyRecommendations for measuring HIV reservoir size in cure-directed clinical trials.Attribution-NonCommercial-NoDerivatives 4.0 Internacional328955732691339-135010.1038/s41591-020-1022-11546-170XNature medicineopen access